FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients
Voltar à Biblioteca de Pesquisa

Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients

May 25, 2026
Share
Pesquisa Emergente

Baseado em pesquisa emergente. Esses achados são promissores, mas requerem validação adicional.

Sobre esta Análise

Este artigo é uma síntese assistida por inteligência artificial de um item noticiário ou lista de ensaios clínicos recentemente publicado. É intenção fornecer uma visão rápida e acessível para a comunidade de pesquisa em peptídeos. Para obter a precisão completa, sempre consulte o

Ozempic Real-world Study to Compare Adherence and Persistence in T2DM Patients

A new study initiated by Novo Nordisk A/S aims to evaluate how well patients adhere to and stay on their medication when using Ozempic (semaglutide) compared with other anti-diabetic drugs for treating type 2 diabetes mellitus (T2DM). This real-world research, listed under NCT07456774 on ClinicalTrials.gov, offers valuable insights into the effectiveness and patient compliance of semaglutide in managing T2DM in China.

Background

Type 2 diabetes is a chronic condition that affects millions of people worldwide. Effective management often involves long-term use of medications to control blood sugar levels and prevent complications such as heart attacks (MACE) and kidney damage. Semaglutide, the active ingredient in Ozempic, has shown promising results in clinical trials for improving glycemic control and reducing cardiovascular risks. However, there is a need to understand how patients respond to this treatment in real-world settings where adherence can be challenging.

The study's primary objective is to assess the incidence of major adverse cardiac events (MACE) and renal complications between Ozempic users and those on other anti-diabetic medications among adult T2DM patients. By comparing these outcomes, researchers hope to provide a clearer picture of semaglutide’s long-term benefits versus traditional treatments.

Key Details

This retrospective study is currently enrolling participants who have already been using either Ozempic or another form of antidiabetic medication. The research team will analyze medical records and patient data to track adherence rates, persistence with treatment, and health outcomes over time.

The inclusion criteria are broad, aiming to include a diverse group of T2DM patients across various age groups, genders, and ethnicities. This comprehensive approach is crucial for ensuring the study's findings can be generalized to different populations.

Novo Nordisk’s initiative underscores the growing importance of real-world evidence in evaluating drug efficacy and safety beyond what randomized controlled trials (RCTs) can provide. By focusing on adherence and persistence rates, this research addresses one of the critical challenges in diabetes management: patient compliance with prescribed treatments.

Key Takeaways

  • Comparative Analysis: The study will compare Ozempic users to those on other anti-diabetic drugs for better understanding of long-term benefits.
  • Patient Adherence: It aims to assess how well patients stick to their medication regimen over time, which is crucial for managing T2DM effectively.
  • Health Outcomes: Researchers will track major adverse cardiac events and renal complications as key indicators of treatment success.
  • Diverse Population: The study includes a wide range of patient demographics to ensure the results are applicable across different groups.

What This Means

For the peptide research community, this study highlights the importance of real-world evidence in evaluating new treatments like semaglutide. By understanding how patients interact with and benefit from these medications outside of controlled settings, researchers can provide more robust recommendations for clinical practice.

Moreover, the findings could influence future regulatory decisions by the FDA regarding peptide therapies. Demonstrating high adherence rates and positive health outcomes may lead to wider adoption of Ozempic in diabetes management protocols.

---

Source: ClinicalTrials.gov — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

Nota do Editor

Esta análise foi gerada usando ferramentas de inteligência artificial e revisada pela equipe editorial da Peptide Contacts. Embora busquemos a precisão, o conteúdo gerado por inteligência artificial pode conter erros ou omissões. Encorajamos os leitores a revisar o fonte original para detalhes completos, metodologia e dados.

A Peptide Contacts fornece resumos de pesquisa curados para fins informativos apenas. Este conteúdo não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.

Comments

Sign in to join the discussion

Este artigo foi gerado usando inteligência artificial e pode conter inaccuracy. É fornecido para fins informativos apenas e não constitui conselhos médicos. Sempre verifique as informações com a fonte original e consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.